Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

4.

Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia.

Baldamus C, Krivoshiev S, Wolf-Pflugmann M, Siebert-Weigel M, Koytchev R, Bronn A.

Adv Ther. 2008 Nov;25(11):1215-28. doi: 10.1007/s12325-008-0111-1.

PMID:
18931828
5.

Cost-effectiveness of epoetin alfa therapy for anemia of end-stage renal disease.

Moran LJ, Carey P, Johnson CA.

Am J Hosp Pharm. 1992 Jun;49(6):1451-4.

PMID:
1529988
7.

Pharmacologic adjuvants to epoetin in the treatment of anemia in patients on hemodialysis.

Berns JS, Mosenkis A.

Hemodial Int. 2005 Jan;9(1):7-22. Review.

PMID:
16191049
8.

Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.

Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R; Epoetin Zeta Study Group.

Curr Med Res Opin. 2008 Mar;24(3):625-37. doi: 10.1185/030079908X273264. Erratum in: Curr Med Res Opin. 2008 Oct;24(10):3007. Curr Med Res Opin. 2008 Apr;24(4):1155.

PMID:
18208642
9.
11.
12.

Intravenous vitamin C can improve anemia in erythropoietin-hyporesponsive hemodialysis patients.

Jacobs C.

Nat Clin Pract Nephrol. 2006 Oct;2(10):552-3. No abstract available.

PMID:
17003830
13.

Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.

Voravud N, Sriuranpong V, Suwanrusme H.

J Med Assoc Thai. 2007 Jun;90(6):1082-8.

PMID:
17624200
14.

Oral ascorbic acid as adjuvant to epoetin alfa in hemodialysis patients with hyperferritinemia.

Nguyen TV.

Am J Health Syst Pharm. 2004 Oct 1;61(19):2007-8. No abstract available.

PMID:
15509119
15.

Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients.

Paganini EP, Eschbach JW, Lazarus JM, Van Stone JC, Gimenez LF, Graber SE, Egrie JC, Okamoto DM, Goodkin DA.

Am J Kidney Dis. 1995 Aug;26(2):331-40.

PMID:
7645538
16.
17.

Current management of anemia in adult hemodialysis patients with end-stage renal disease.

Frankenfield DL, Johnson CA.

Am J Health Syst Pharm. 2002 Mar 1;59(5):429-35.

PMID:
11887409
18.

Ascorbic acid for anemia management in hemodialysis patients: a systematic review and meta-analysis.

Deved V, Poyah P, James MT, Tonelli M, Manns BJ, Walsh M, Hemmelgarn BR; Alberta Kidney Disease Network.

Am J Kidney Dis. 2009 Dec;54(6):1089-97. doi: 10.1053/j.ajkd.2009.06.040. Epub 2009 Sep 23. Review.

PMID:
19783342
19.

Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.

Vincent JL, Spapen HD, Creteur J, Piagnerelli M, Hubloue I, Diltoer M, Roman A, Stevens E, Vercammen E, Beaver JS.

Crit Care Med. 2006 Jun;34(6):1661-7.

PMID:
16607233
20.

The clinical effects of recombinant human erythropoietin for the treatment of anemia in end stage renal disease patients on dialysis.

Uthayanaka Y, Jirajan B, Krairithichai U, Jantavanich N.

Southeast Asian J Trop Med Public Health. 1993 Sep;24(3):577-82.

PMID:
8160072
Items per page

Supplemental Content

Write to the Help Desk